SEARCH

SEARCH BY CITATION

References

  • 1
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 1735.
  • 2
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 3
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 4
    Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferonα2b plus ribavirin for 48 weeks or for 24 weeks versus interferonα2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 142632.
  • 5
    Davis GL. Treatment of chronic hepatitis C. Br Med J 2001; 323: 11412.
  • 6
    Tappero G, Ballare M, Farina M, et al. Severe anaemia following combined α-interferon/ribavirin therapy of chronic hepatitis C. J Hepatol 1998; 29(6): 10334.
  • 7
    Saab S, Martin P. Hemolytic anaemia and the treatment of chronic hepatitis C. J Clin Gastroenterol 1999; 28(4): 28990.
  • 8
    Vlierberghe HV, Delanghe JR, Vos MD, et al. Factors influencing ribavirin-induced haemolysis. J Hepatol 2001; 34: 9116.
  • 9
    McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl. 1): 5765.
  • 10
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(Suppl. 1): 6775.
  • 11
    Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously non-responsive to interferon. A meta-analysis of randomized trials. J Am Med Assoc 2001; 285: 1939.
  • 12
    Detsky AS, Naylor CD, O'Rourke K, et al. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992; 45(3): 25565.
  • 13
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 14
    Andreone P, Gramenzi A, Cursaro C, et al. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: results of a randomized multicenter trial. JHepatol 1999; 30: 78893.
  • 15
    Barbaro G, Lorenzo GD, Soldini M, et al. Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93: 244551.
  • 16
    Barbaro G, Lorenzo GD, Belloni G, et al. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999; 107: 1128.
  • 17
    Bell H, Hellum K, Harthug S, et al. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scand J Gastroenterol 1999; 34: 1948.
  • 18
    Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 8127.
  • 19
    Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23(Suppl. 2): 812.
  • 20
    Davis GL, Esteban-Mur R, Rustgl V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 14939.
  • 21
    Di Bisceglie AM, Confeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897903.
  • 22
    Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 5918.
  • 23
    Kakumu S, Yoshioka K, Wakita T, et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 50712.
  • 24
    Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. J Clin Pharmacol 1998; 46: 56370.
  • 25
    Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 130712.
  • 26
    Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebo-controlled trial of interferonα-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 837.
  • 27
    Salmeron J, Ruiz-Extremera A, Torres C, et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver 1999; 19: 27580.
  • 28
    Sostegni R, Ghisefti V, Pittaluga F, et al. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998; 28: 3416.
  • 29
    Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 9616.
  • 30
    Schalm SW, Weiland O, Hansen BE, et al. Interferon–ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117: 40813.
  • 31
    Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 1994; 140(3): 2906.
  • 32
    Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997; 98: 8505.
  • 33
    De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anaemia by ribavirin therapy in patients with chronichepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 9971004.